Table 5 Perception of satisfactory outcomes and side effects according to treatment
Mean | SD | ||
|---|---|---|---|
sgAH (normal doses) | % of patients with satisfactory outcomes | 64.7 | 26.8 |
% of patients without side effects | 42.1 | 32.1 | |
% of patients with level of collaboration | 73.6 | 30.4 | |
sgAH (higher doses) | % of patients with satisfactory outcomes | 62.3 | 30.7 |
% of patients without side effects | 45.2 | 32.2 | |
% of patients with level of collaboration | 70.6 | 31.6 | |
ssAH + AH2 blocker | % of patients with satisfactory outcomes | 60.2 | 32.1 |
% of patients without side effects | 50.3 | 99.2 | |
% of patients with level of collaboration | 83.5 | 99.9 | |
sgAH + antileukotrienes | % of patients with satisfactory outcomes | 54.7 | 31.5 |
% of patients without side effects | 52.0 | 32.7 | |
% of patients with level of collaboration | 60.9 | 33.1 | |
ssAH + AH2 blocker + antileukotrienes | % of patients with satisfactory outcomes | 55.9 | 32.4 |
% of patients without side effects | 47.8 | 32.5 | |
% of patients with level of collaboration | 72.6 | 30.3 |